Search peptides, terms, sources/
Research source · 2026

Setmelanotide for the Treatment of Acquired Hypothalamic Obesity

About this source

Kind
Research
Design
Human clinical trial, RCT
Population
120 people (mean age 19.9, range 4 to 66) with acquired hypothalamic obesity; 81 on setmelanotide, 39 on placebo
Sample size
120
Primary or secondary
primary
Peer review
peer reviewed
Retraction status
None known
Date checked
14 November 2026

Limitations

Single phase 3 trial of 52 weeks. Serious adverse events were more frequent on setmelanotide. Mixed ages (4 to 66), so results may not apply equally to each group.

Cited in

Spotted an error? Report a problem with this page. We correct the record and log every change on What's changed.